These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 9270626)

  • 21. Nursing management of MS patients receiving interferon beta-1b therapy.
    Costello K; Conway K
    Rehabil Nurs; 1997; 22(2):62-6, 81. PubMed ID: 9110845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis].
    Tilbery CP; Moreira MA; Mendes MF; Lana-Peixoto MA
    Arq Neuropsiquiatr; 2000 Sep; 58(3A):769-76. PubMed ID: 10973126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis.
    Schwartz CE; Coulthard-Morris L; Cole B; Vollmer T
    Arch Neurol; 1997 Dec; 54(12):1475-80. PubMed ID: 9400356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon beta-1b for the treatment of multiple sclerosis.
    Petri T; Weber-Diehl F
    J Biotechnol; 1995 Nov; 43(1):74-5. PubMed ID: 8573325
    [No Abstract]   [Full Text] [Related]  

  • 25. Newer versus older treatments for relapsing-remitting multiple sclerosis.
    Weinstock-Guttman B; Cohen JA
    Drug Saf; 1996 Feb; 14(2):121-30. PubMed ID: 8852526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis.
    Mohr DC; Goodkin DE; Likosky W; Gatto N; Baumann KA; Rudick RA
    Arch Neurol; 1997 May; 54(5):531-3. PubMed ID: 9152109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The treatment of multiple sclerosis: current and future.
    Polman CH; Hartung HP
    Curr Opin Neurol; 1995 Jun; 8(3):200-9. PubMed ID: 7551119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon beta-1B--hope or hype?
    Drug Ther Bull; 1996 Feb; 34(2):9-11. PubMed ID: 8819985
    [No Abstract]   [Full Text] [Related]  

  • 29. [Interferons beta in patients with multiple sclerosis].
    Vlasov IaV; Kuznetsova NI; Poverennova IE; Khivintseva EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):54-5. PubMed ID: 16117149
    [No Abstract]   [Full Text] [Related]  

  • 30. [Report from the Satellite Symposium: Leading the way: outstanding efficacy of interferon beta-1b right from the start. Berlin, Germany, 06.24.2002].
    Cendrowski W
    Neurol Neurochir Pol; 2002; 36(6):1260-3. PubMed ID: 12715704
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy and safety of prolonged immunomodulatory treatment with interferon beta.
    Demina TL; Khachanova NV; Davydovskaya MV; Popova NF; Gusev EI
    Neurosci Behav Physiol; 2009 Jun; 39(5):497-9. PubMed ID: 19430980
    [No Abstract]   [Full Text] [Related]  

  • 32. [The use of beta-interferon-1b in children and adolescents with multiple sclerosis].
    Bykova OV; Kuzenkova LM; Maslova OI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(9):29-33. PubMed ID: 17069059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon beta-1b.
    Goodkin DE
    Lancet; 1994 Oct; 344(8929):1057-60. PubMed ID: 7934448
    [No Abstract]   [Full Text] [Related]  

  • 34. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b.
    Schwid SR; Goodman AD; Mattson DH
    Arch Neurol; 1997 Sep; 54(9):1169-90. PubMed ID: 9311363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of magnetic resonance imaging sensitivity in patients with relapsing remitting multiple sclerosis: baseline versus Betaseron treatment trials.
    Frank JA; Bash C; Stone L; Petrella J; Maloni H; McFarland H
    Acad Radiol; 1996 Aug; 3 Suppl 2():S173-5. PubMed ID: 8796554
    [No Abstract]   [Full Text] [Related]  

  • 36. Trial of interferon-beta in multiple sclerosis stopped early.
    Bonn D
    Lancet; 1998 Feb; 351(9102):573. PubMed ID: 9492786
    [No Abstract]   [Full Text] [Related]  

  • 37. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes.
    Frohman EM; Racke M; van Den Noort S
    Arch Neurol; 2000 Jul; 57(7):930-2. PubMed ID: 10891973
    [No Abstract]   [Full Text] [Related]  

  • 38. Interferon beta-1a and beta-1b for treatment of multiple sclerosis.
    Kappos L
    Lancet; 2002 Nov; 360(9343):1428; author reply 1428-9. PubMed ID: 12424020
    [No Abstract]   [Full Text] [Related]  

  • 39. Interferon beta-1a in primary progressive multiple sclerosis.
    Leary SM; Thompson AJ
    J Neurol Sci; 2003 Feb; 206(2):215-6. PubMed ID: 12559514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Interferon beta-1b in multiple sclerosis--news regarding open questions].
    Nervenarzt; 1997 Aug; 68(8 Suppl Interferon):1-4. PubMed ID: 9380220
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.